Patients from 40 states & 3 countries
Our patients have traveled from around the world for our leading-edge programs, clinical trials, personalized treatment plans and quality of life and survivorship programs for both adult and pediatric brain tumor patients.
100+ physicians, researchers, scientists and staff
Our team at the Wells Center for Brain Tumor Therapy at UF includes experts in several specialties, including specialty surgical care, radiation therapy, laser ablation therapy, neuro-oncology care, genetic testing and precision medicine.
Over $10 million a year invested in research funding
From immunotherapy to chemotherapy, optune therapy and unique clinical trials, we are leading the country in searching for a cure for brain tumors.
Listed below are the clinical trials that we are currently enrolling at UF.
If you are interested in being screened for a clinical trial, please email Wells-BTC@UFL.edu and one of our clinical research coordinators will follow up with you as quickly as possible.
Fast Facts
Our clinical trials portfolio includes:
- More than 40 research studies
- More than 10 Pediatric-focused studies
- Five phase-1 Trials
- First-In-Human treatments
- Investigational New Drugs developed at UF
Featured Trial
IMPACT
Phase I Study —To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T cell Therapy in CD70+ Adult GBM and Pediatric High-Grade Gliomas (pHGG)
Subject Inclusion criteria:
- Adult
- Age: At least 18 years of age
- Newly-diagnosed de novo GBM based on the absence of previous history of brain tumor (WHO Grade IV glioma) by histopathology or molecular studies. (secondary GBM not eligible)
- Tumor must have a supratentorial component
- CD70 positive (≥20%, 1+)
- Tumor testing will be performed as part of study screening
- Pediatric
- Ages four to >18 years old
- Newly-diagnosed pHGG based on the absence of previous history of brain tumor (WHO Grade III-IV glioma) by histopathology
- CD70 positive (≥20%, 1+)
- Tumor testing will be performed as part of study screening
See full inclusion criteria and learn more about the IMPACT Clinical Trial (Link to the CT.gov https://classic.clinicaltrials.gov/ct2/show/NCT05353530)
Contact Phuong Deleyrolle to hear more about the IMPACT Clinical Trial (phuong.deleyrolle@neurosurgery.ufl.edu)
PNOC 020
A Phase I/II Study of RNA-lipid particle (RNA-LP) vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM).
- Please note:
- Surgical resection is required to be performed at UF.
- Enrollment must occur in person at UF prior to surgery or any treatment modalities
Adult Subject Inclusion Criteria:
- Age: 21 Years and older (Adult, Older Adult)
- Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma) (secondary GBM not eligible) that is MGMT unmethylated.
- The tumor must have a supratentorial component.
- Bone Marrow, Renal and Hepatic tests
Pediatric Subject Inclusion Criteria:
- > 3 years
- No Methylation requirement
- The Tumor must have a supratentorial component.
- Bone Marrow, Renal, and Hepatic tests
See full inclusion criteria and learn more about the PNOC 020 Clinical Trial
Contact Marcia Hodik to hear more about the PNOC 020 Clinical Trial.
Browse or search current neurosurgery clinical trials
ADAGiO
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients.
IMPACT-Adult
Phase I Study —To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T cell Therapy in CD70+ Adult GBM and Pediatric High-Grade Gliomas (pHGG)
• Adult
• Age: At least 18 years of age
• Newly-diagnosed de novo GBM based on the absence of previous history of brain tumor (WHO Grade IV glioma) by histopathology or molecular studies. (secondary GBM not eligible)
• Tumor must have a supratentorial component
• CD70 positive (≥20%, 1+)
• Tumor testing will be performed as part of study screening
IMPACT-Peds
Phase I Study —To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T cell Therapy in CD70+ Adult GBM and Pediatric High-Grade Gliomas (pHGG)
• Ages four to >18 years old
• Tumor must have a supratentorial component
• CD70 positive (≥20%, 1+)
• Tumor testing will be performed as part of study screening
• Newly-diagnosed pHGG based on the absence of previous history of brain tumor (WHO Grade III-IV glioma) by histopathology
MATCHPOINT
MATCHPOINT: Medulloblastoma Adoptive T cell therapy, DC vaccines, and Hematopoietic stem cells combined with immune checkPOINT blockade
OPTIMUS Prime
OPTIMUS PRIME: Safety and feasibility of OPTune Integrated with MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd
Trial
PEACH
Precision mEdicine and Adoptive Cellular tHerapy for the treatment of recurrent neuroblastoma and newly diagnosed diffuse intrinsic pontine glioma (DIPG).
Peds CHAMP1ON
Combinatorial Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade Phase 1 Trial for RecurreNt Pediatric High-Grade Glioma
RNA Prime
RNA PRIME: RNA lipid particles targeting Pediatric Recurrent Intracranial Malignancies and other systEmic solid tumors